

Erratum to: Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice

Carlos J. Gonzalez-Quesada · Robert P. Giugliano

Published online: 29 April 2014
© Springer International Publishing Switzerland 2014

**Erratum to: Am J Cardiovasc Drugs (2014) 14:111–127
DOI 10.1007/s40256-013-0062-z**

Page 115, Fig. 1, Parts A and C which previously showed:

the dosing schedule for dabigatran as 150 mg QD and 110 mg QD and for apixaban as 5 mg QD, respectively

should show:

the dosing schedule for dabigatran as 150 mg BID and 110 mg BID and for apixaban as 5 mg BID, respectively

Page 116, Table 2, column 2 (RE-LY), the aspirin dose which previously read as:

not specified

should read as:

>100 mg/day excluded

Page 121–122, Table 4, column 1, the last three rows which previously read as:

(annualized %)

should read as:

(%)

The online version of the original article can be found under doi:[10.1007/s40256-013-0062-z](https://doi.org/10.1007/s40256-013-0062-z).

C. J. Gonzalez-Quesada
Department of Medicine, Brigham and Women's Hospital,
75 Francis St., Phyllis Jen Center for Primary Care (Suite A),
Boston, MA 02115, USA

R. P. Giugliano (✉)
TIMI Study Group, Cardiovascular Division, Brigham and
Women's Hospital, 350 Longwood Ave., 1st Floor Offices,
Boston, MA 02115, USA
e-mail: rgiugliano@partners.org